UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2019
Commission File Number 001-34566
China Biologic Products Holdings, Inc.
(Exact name of registrant as specified in its charter)
18th Floor, Jialong International Building, 19 Chaoyang Park Road
Chaoyang District, Beijing 100125
People’s Republic of China
(+86) 10-6598-3111
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-Fx Form 40-F¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):¨
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):¨
Note:Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
On February 1, 2019, Mr. Zhijun Tong informed China Biologic Products Holdings, Inc. (the “Company”) that he was resigning from his positions as the president and a director of the Company due to personal reasons, effective immediately, and that his decision to resign did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
On February 3, 2019, the board of directors (the “Board”) of the Company unanimously elected Mr. Joseph Chow to be the new chairman of the Board in succession to Mr. David Hui Li. Mr. Li continues to serve as a director on the Board.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. |
| | | |
| | | |
| Date: | February 4, 2019 | | By: | /s/ Joseph Chow |
| | | | | Name: | Joseph Chow |
| | | | | Title: | Chairman of the Board of Directors |
